Necrotizing Soft Tissue Infection
18
5
5
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.7%
3 terminated out of 18 trials
62.5%
-24.0% vs benchmark
11%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (18)
Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).
MicroMatrix® Flex in Tunneling Wounds
Myriad™ Augmented Soft Tissue Reconstruction Registry
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Necrotizing Soft Tissue Infections
The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®
HAT for the Treatment of Sepsis Associated With NASTI
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Characteristics of Patients With Necrotizing Soft Tissue Infections
Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation
SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections
Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
Biomarkers in Patients With Flesh-eating Bacterial Infections